Gadolinium, the contrast dye used in MRIs and MRAs has come under fire from the FDA. In 2007, the agency issued a black box warning. This is the most severe warning a medication or drug can have. Then, additional concerns sparked an FDA review of all gadolinium products. However, researchers have been citing dangers with this chemical agent as early as 1984. Other countries have recalled or banned the substance but not the U.S.
About Gadolinium
Gadolinium is a chemical element carrying the atomic number 64 and the atomic symbol Gd. Belonging to a group of elements in the periodic table called Lanthanides, the chemical is a rare earth element. It is typically used in microwave applications, color TV tubes, synthetic gemstones, compact discs, and computer memory. This chemical element is widely used as an injectable contrast agent when patients undergo Magnetic Resonance Imaging (MRI) and Magnetic Resonance Angiography (MRA) scans. Research has found that this chemical element is a toxic metal and any amount that remains in the brain and other parts of the body has the potential to have a harmful effect. The long-term effects of gadolinium deposition are still unknown as research is ongoing.
Gadolinium Recalled
There have been a number of meetings and recalls in other countries. In March 2017, The European Medicines Agency (EMA) recommended linear agents be removed from the market including, MultiHance, Optimark, Omniscan, and Magnevist. Then, on July 20, 2017, the EMA suspended the use of GBCAs. In 2017, Japan and Singapore restricted their use, and the UK suspended production the following month.
FDA Action
In 2005, the FDA announced an investigation into the risk of brain deposits before issuing a black box warning in 2007. Ten years later, Medical Imaging Drug Advisory Committee (MIDAC) recommended adding a warning identifying that the body could retain gadolinium following an MRI. Also, the risk is higher with linear GBCAs. A month later, the FDA issued a warning gadolinium retention from MRI contrast agents, specifically regarding the increased risk of linear GBCAs.
However, medical professionals still use linear GBCAs in up to 50% of all imaging scans. They believe they are harmless, however many have long-lasting painful side effects.
Free Case Evaluation
A gadolinium lawsuit may be an option for patients suffering from gadolinium retention and related complications. Gadolinium, used in dyes to increase the clarity of MRI and MRA scans, can create chemical element retention in the body, Therefore, this increases the risk of gadolinium deposition disease. This condition is accompanied by symptoms that include severe physical pain and cognitive difficulties. Affected patients and their loved ones may be able to file a lawsuit and recover damages.
For more information, contact The Michael Brady Lynch Firm. We offer free, confidential, no-obligation consultations. We have over 20 years experience helping consumers injured by unsafe products manufactured by large companies.